BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨

路透中文

Jan 21

BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨

1月21日 - ** 药物开发商Lexicon Pharmaceuticals LXRX.O股价盘前上涨2.16%至1.34美元

** 该公司称 (link) 美国 FDA 批准了其治疗糖尿病神经痛的实验性药物 pilavapadin 的后期试验

** 糖尿病神经痛是由长期高血糖损害神经引起的一种疾病

** 该公司称，这项为期12周的研究将测试每天10毫克剂量的实验性非阿片类药物与安慰剂的效果。

** LXRX公司的pilavapadin能阻断一种参与疼痛信号传导的蛋白质，早期测试表明这种药物能减轻疼痛，但不会影响阿片类药物的通路。

** 公司表示，美国食品药品管理局没有要求进行更多研究

** 2025 年股价上涨约 56%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605006041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605006041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605006041?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-21 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605006041","market":"hk","top_or_hot":-1,"title":"BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨</title></head><body><p><span>1月21日</span><span> - </span>** 药物开发商Lexicon Pharmaceuticals <span>LXRX.O</span>股价盘前上涨2.16%至1.34美元</p><p>** 该公司称 (link) 美国 FDA 批准了其治疗糖尿病神经痛的实验性药物 pilavapadin 的后期试验</p><p>** 糖尿病神经痛是由长期高血糖损害神经引起的一种疾病</p><p>** 该公司称，这项为期12周的研究将测试每天10毫克剂量的实验性非阿片类药物与安慰剂的效果。</p><p>** LXRX公司的pilavapadin能阻断一种参与疼痛信号传导的蛋白质，早期测试表明这种药物能减轻疼痛，但不会影响阿片类药物的通路。</p><p>** 公司表示，<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品管理局没有要求进行更多研究</p><p>** 2025 年股价上涨约 56% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-21 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨</title></head><body><p><span>1月21日</span><span> - </span>** 药物开发商Lexicon Pharmaceuticals <span>LXRX.O</span>股价盘前上涨2.16%至1.34美元</p><p>** 该公司称 (link) 美国 FDA 批准了其治疗糖尿病神经痛的实验性药物 pilavapadin 的后期试验</p><p>** 糖尿病神经痛是由长期高血糖损害神经引起的一种疾病</p><p>** 该公司称，这项为期12周的研究将测试每天10毫克剂量的实验性非阿片类药物与安慰剂的效果。</p><p>** LXRX公司的pilavapadin能阻断一种参与疼痛信号传导的蛋白质，早期测试表明这种药物能减轻疼痛，但不会影响阿片类药物的通路。</p><p>** 公司表示，<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品管理局没有要求进行更多研究</p><p>** 2025 年股价上涨约 56% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXRX","symbol_name":"莱斯康制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4T3YM1BZ:1","article_id":"2605006041","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605006041","pubTimestamp":1769003179,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨1月21日 - ** 药物开发商Lexicon Pharmaceuticals LXRX.O股价盘前上涨2.16%至1.34美元** 该公司称  美国 FDA 批准了其治疗糖尿病神经痛的实验性药物 pilavapadin 的后期试验** 糖尿病神经痛是由长期高血糖损害神经引起的一种疾病** 该公司称，这项为期12周的研究将测试每天10毫克剂量的实验性非阿片类药物与安慰剂的效果。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LXRX":"莱斯康制药","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Lexicon Stock Rises as BUZZ-FDA Approves Late-Stage Testing of Diabetic Neuralgia Drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXRX":0.9},"content_text":"BUZZ-FDA批准糖尿病神经痛药物后期测试，Lexicon股价上涨1月21日 - ** 药物开发商Lexicon Pharmaceuticals LXRX.O股价盘前上涨2.16%至1.34美元** 该公司称 (link) 美国 FDA 批准了其治疗糖尿病神经痛的实验性药物 pilavapadin 的后期试验** 糖尿病神经痛是由长期高血糖损害神经引起的一种疾病** 该公司称，这项为期12周的研究将测试每天10毫克剂量的实验性非阿片类药物与安慰剂的效果。** LXRX公司的pilavapadin能阻断一种参与疼痛信号传导的蛋白质，早期测试表明这种药物能减轻疼痛，但不会影响阿片类药物的通路。** 公司表示，美国食品药品管理局没有要求进行更多研究** 2025 年股价上涨约 56% (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}